Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the global fourth quarter net sales of OLYSIO® (simeprevir) amounted to 44 MUSD. The royalty for the third quarter amounted to 31 MSEK (3.4 MEUR). Medivir’s royalties based on sales for the fourth quarter are calculated from the third royalty tier. +---------------------------+--------+-------+-------+ |OLYSIO® global net sales |Sales in MUSD | | +---------------------------+--------+-------+-------+ |Market |Q4 -2015|Q4-2014|Change | +---------------------------+--------+-------+-------+ |US |-1 |256 |-100% | +---------------------------+--------+-------+-------+ |RoW |45 |65 |-31% | +---------------------------+--------+-------+-------+ |Total global net sales MUSD|44 |321 |-86% | +---------------------------+--------+-------+-------+ Medivir will publish its Financial Statement 2015 on February 18 2016, at 8.30 CET, followed by a conference call for investors, analysts and the media at 14.00 CET. More information about the conference call/webcast will be posted at www.medivir.com. For more information please contact: Ola Burmark, CFO, Medivir AB, mobile: +46 725 480 580 Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 13.30 CET on 26 January 2016. About Medivir Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.
OLYSIO® sales during the fourth quarter 2015
| Source: Medivir AB
Attachments
